The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Setoperona     3-[2-[4-(4- fluorophenyl)carbonyl-1...

Synonyms: Setoperone, SEPTOPERONE, Setoperonum, SureCN122185, AG-K-19121, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

High impact information on Setoperone

  • In this study, we assessed brain 5-HT(2) receptors in 20 depressed patients (mean +/- SD age, 40.1 +/- 9.5 years; range, 22-60 years) and 20 healthy controls similar in age (37.2 +/- 12.6 years; range, 19-59 years) using positron emission tomography and setoperone labeled with fluorine 18 ([(18)F]setoperone) [1].
  • Depressed patients showed a significant decrease in 5-HT2 receptor binding as measured by setoperone binding in frontal, temporal, parietal, and occipital cortical regions following desipramine treatment [2].
  • Our purpose, therefore, was to assess the effects of treatment with desipramine hydrochloride on brain 5-HT2 receptors in depressed patients using positron emission tomography (PET) and fluorine-18 (18F)-labeled setoperone [2].
  • RESULTS: A dose-dependent decrease in the number of available cortical binding sites for [18F] setoperone was demonstrated in the chlorpromazine group; for the highest dose, there was a virtual lack of sites available for binding [3].
  • These data indicate that [18F]setoperone (a) is significantly bound to plasma proteins and (b) is significantly metabolized into several labeled metabolites that are much more hydrophilic than setoperone and, hence, presumably do not cross the blood-brain barrier [4].

Biological context of Setoperone


Anatomical context of Setoperone


Associations of Setoperone with other chemical compounds

  • Effect of serotonin antagonism in schizophrenia: a pilot study with setoperone [7].
  • Conversely, several compounds which possess appreciable activity at 5-HT2 sites in ex vivo binding assays, but possess little activity at D-2 sites (i.e., pirenperone, setoperone, fluperlapine and clozapine), all produced large increases in striatal DA metabolism [8].
  • In contrast, some atypical APD or its candidates (clozapine, 5-30 mg/kg; fluperlapine, 10 mg/kg; risperidone, 0.25-3 mg/kg; setoperone, 0.025-0.25 mg/kg; ORG 5222, 0.25 mg/kg) showed considerable occupation of 5-HT2 receptors in cerebral cortex with smaller or negligible occupation of D2 and D1 receptors [9].

Gene context of Setoperone


  1. Brain serotonin2 receptors in major depression: a positron emission tomography study. Yatham, L.N., Liddle, P.F., Shiah, I.S., Scarrow, G., Lam, R.W., Adam, M.J., Zis, A.P., Ruth, T.J. Arch. Gen. Psychiatry (2000) [Pubmed]
  2. Decrease in brain serotonin 2 receptor binding in patients with major depression following desipramine treatment: a positron emission tomography study with fluorine-18-labeled setoperone. Yatham, L.N., Liddle, P.F., Dennie, J., Shiah, I.S., Adam, M.J., Lane, C.J., Lam, R.W., Ruth, T.J. Arch. Gen. Psychiatry (1999) [Pubmed]
  3. Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. Trichard, C., Paillère-Martinot, M.L., Attar-Levy, D., Recassens, C., Monnet, F., Martinot, J.L. The American journal of psychiatry. (1998) [Pubmed]
  4. A method for the in vivo investigation of the serotonergic 5-HT2 receptors in the human cerebral cortex using positron emission tomography and 18F-labeled setoperone. Blin, J., Sette, G., Fiorelli, M., Bletry, O., Elghozi, J.L., Crouzel, C., Baron, J.C. J. Neurochem. (1990) [Pubmed]
  5. Down regulation of serotonin-S2 receptor sites in rat brain by chronic treatment with the serotonin-S2 antagonists: ritanserin and setoperone. Leysen, J.E., Van Gompel, P., Gommeren, W., Woestenborghs, R., Janssen, P.A. Psychopharmacology (Berl.) (1986) [Pubmed]
  6. 5-HT2-receptor antagonists: alpha 1- vs. 5-HT2-receptor blocking properties in blood vessels. Cohen, M.L., Schenck, K.W., Kurz, K.D. J. Cardiovasc. Pharmacol. (1988) [Pubmed]
  7. Effect of serotonin antagonism in schizophrenia: a pilot study with setoperone. Ceulemans, D.L., Gelders, Y.G., Hoppenbrouwers, M.L., Reyntjens, A.J., Janssen, P.A. Psychopharmacology (Berl.) (1985) [Pubmed]
  8. 5-HT2 receptor blockade by ICI 169,369 and other 5-HT2 antagonists modulates the effects of D-2 dopamine receptor blockade. Saller, C.F., Czupryna, M.J., Salama, A.I. J. Pharmacol. Exp. Ther. (1990) [Pubmed]
  9. Dopamine D1, D2 and serotonin2 receptor occupation by typical and atypical antipsychotic drugs in vivo. Matsubara, S., Matsubara, R., Kusumi, I., Koyama, T., Yamashita, I. J. Pharmacol. Exp. Ther. (1993) [Pubmed]
  10. Effects of 5-HT1A agonists and 5-HT2 antagonists on haloperidol-induced dyskinesias in squirrel monkeys: no evidence for reciprocal 5-HT-dopamine interaction. Liebman, J.M., Gerhardt, S.C., Gerber, R. Psychopharmacology (Berl.) (1989) [Pubmed]
WikiGenes - Universities